587 related articles for article (PubMed ID: 22141384)
1. Triazole antifungal agents in invasive fungal infections: a comparative review.
Lass-Flörl C
Drugs; 2011 Dec; 71(18):2405-19. PubMed ID: 22141384
[TBL] [Abstract][Full Text] [Related]
2. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
[TBL] [Abstract][Full Text] [Related]
3. Network Meta-analysis and Pharmacoeconomic Evaluation of Fluconazole, Itraconazole, Posaconazole, and Voriconazole in Invasive Fungal Infection Prophylaxis.
Zhao YJ; Khoo AL; Tan G; Teng M; Tee C; Tan BH; Ong B; Lim BP; Chai LY
Antimicrob Agents Chemother; 2016 Jan; 60(1):376-86. PubMed ID: 26525782
[TBL] [Abstract][Full Text] [Related]
4. Posaconazole: an extended-spectrum triazole antifungal agent.
Schiller DS; Fung HB
Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
[TBL] [Abstract][Full Text] [Related]
5. Triazole antifungals used for prophylaxis and treatment of invasive fungal disease in adult haematology patients: Trough serum concentrations in relation to outcome.
Ceesay MM; Couchman L; Smith M; Wade J; Flanagan RJ; Pagliuca A
Med Mycol; 2016 Oct; 54(7):691-8. PubMed ID: 27161786
[TBL] [Abstract][Full Text] [Related]
6. [Triazole antifungal agents: practice guidelines of therapeutic drug monitoring and perspectives in treatment optimization].
Scodavolpe S; Quaranta S; Lacarelle B; Solas C
Ann Biol Clin (Paris); 2014; 72(4):391-404. PubMed ID: 25119797
[TBL] [Abstract][Full Text] [Related]
7. Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent.
Nagappan V; Deresinski S
Clin Infect Dis; 2007 Dec; 45(12):1610-7. PubMed ID: 18190324
[TBL] [Abstract][Full Text] [Related]
8. Antifungal agents.
Chen SC; Sorrell TC
Med J Aust; 2007 Oct; 187(7):404-9. PubMed ID: 17908006
[TBL] [Abstract][Full Text] [Related]
9. Voriconazole : a review of its use in the management of invasive fungal infections.
Scott LJ; Simpson D
Drugs; 2007; 67(2):269-98. PubMed ID: 17284090
[TBL] [Abstract][Full Text] [Related]
10. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.
Fera MT; La Camera E; De Sarro A
Expert Rev Anti Infect Ther; 2009 Oct; 7(8):981-98. PubMed ID: 19803707
[TBL] [Abstract][Full Text] [Related]
11. Update on azole antifungals.
Zonios DI; Bennett JE
Semin Respir Crit Care Med; 2008 Apr; 29(2):198-210. PubMed ID: 18366001
[TBL] [Abstract][Full Text] [Related]
12. Posaconazole: Use in the Prophylaxis and Treatment of Fungal Infections.
Clark NM; Grim SA; Lynch JP
Semin Respir Crit Care Med; 2015 Oct; 36(5):767-85. PubMed ID: 26398542
[TBL] [Abstract][Full Text] [Related]
13. New and investigational triazole agents for the treatment of invasive fungal infections.
De Sarro A; La Camera E; Fera MT
J Chemother; 2008 Dec; 20(6):661-71. PubMed ID: 19129062
[TBL] [Abstract][Full Text] [Related]
14. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
Pfaller MA; Messer SA; Hollis RJ; Jones RN;
Antimicrob Agents Chemother; 2002 Apr; 46(4):1032-7. PubMed ID: 11897586
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.
Stockmann C; Constance JE; Roberts JK; Olson J; Doby EH; Ampofo K; Stiers J; Spigarelli MG; Sherwin CM
Clin Pharmacokinet; 2014 May; 53(5):429-54. PubMed ID: 24595533
[TBL] [Abstract][Full Text] [Related]
16. Posaconazole: clinical pharmacology and potential for management of fungal infections.
Groll AH; Walsh TJ
Expert Rev Anti Infect Ther; 2005 Aug; 3(4):467-87. PubMed ID: 16107193
[TBL] [Abstract][Full Text] [Related]
17. The cost-utility analysis of antifungal prophylaxis for invasive fungal infections in acute myeloid leukaemia patients receiving chemotherapy: a study from a middle-income country.
Pungprasert T; Dhirachaikulpanich D; Phutthasakda W; Tantai N; Maneeon S; Nganthavee V; Atipas K; Tanpong S; Krithin S; Tanglitanon S; Jutidamrongphan W; Chayakulkeeree M; Srinonprasert V; Phikulsod P
J Hosp Infect; 2024 Mar; 145():118-128. PubMed ID: 38219835
[TBL] [Abstract][Full Text] [Related]
18. Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period.
Ananda-Rajah MR; Grigg A; Downey MT; Bajel A; Spelman T; Cheng A; Thursky KT; Vincent J; Slavin MA
Haematologica; 2012 Mar; 97(3):459-63. PubMed ID: 22058198
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant.
Solano C; Slavin M; Shaul AJ; Marks DI; Cordonnier C; Cornely OA; Pagliuca A; Cragin L; Jarque I; Garcia-Vidal C; Sorensen S; Vanness DJ; Charbonneau C; Barrueta JA; Peral C; De Salas-Cansado M; Bow EJ
Mycoses; 2017 Feb; 60(2):79-88. PubMed ID: 27562016
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic/pharmacodynamic profile of posaconazole.
Li Y; Theuretzbacher U; Clancy CJ; Nguyen MH; Derendorf H
Clin Pharmacokinet; 2010 Jun; 49(6):379-96. PubMed ID: 20481649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
